Biopharma & Life Sciences
Standard Biotools Executive Compensation (FY25)
LAB · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): June 18, 2026
151 figures on this page: 140 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Standard Biotools' chief executive and what were they paid?
Michael Egholm, President, Chief Executive Officer, and Director, received $8,823,502 in total compensation for fiscal 2025.
What was Standard Biotools' say-on-pay result?
Shareholders supported the say-on-pay proposal with 84.0% of votes cast including abstentions in favor at the meeting held June 17, 2026 for fiscal 2025.
Which companies are in Standard Biotools' peer group?
The disclosed peer group includes Adaptive Biotechnologies Corporation, Azenta, Inc., CareDx, Inc., Castle Biosciences, Inc. and Cryoport, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Egholm President, Chief Executive Officer, and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Alex Kim Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Sean Mackay Chief Business Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Alex Kim | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Alex Kim | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael Egholm | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael Egholm | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sean Mackay | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Alex Kim | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael Egholm | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Sean Mackay | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Thomas Carey Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Frank Witney | ◇ | ◇ | ◇ | — | — | — | ◇ |
Fenel M. Eloi | ◇ | ◇ | ◇ | — | — | — | ◇ |
Troy Cox | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kathy Hibbs | ◇ | ◇ | ◇ | — | — | — | ◇ |
Eli Casdin | ◇ | ◇ | ◇ | — | — | — | ◇ |
Michael Egholm served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Adaptive Biotechnologies Corporation ADPT
- Azenta, Inc. AZTA
- CareDx, Inc. CDNA
- Castle Biosciences, Inc. CSTL
- Cryoport, Inc. CYRX
- Cytek Biosciences, Inc. CTKB
- Deciphera Pharmaceuticals, Inc. DCPH
- Guardant Health, Inc. GH
- Halozyme Therapeutics, Inc. HALO
- Maravai LifeSciences Holdings, Inc. MRVI
- Mesa Laboratories, Inc. MLAB
- Mirum Pharmaceuticals, Inc. MIRM
- NeoGenomics, Inc. NEO
- OraSure Technologies, Inc. OSUR
- Pacific Biosciences of California, Inc. PACB
- Quanterix Corporation QTRX
- Surmodics, Inc. SRDX
- Twist Bioscience Corporation TWST
- Veracyte, Inc. VCYT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 17, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 18, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | July 1, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 14, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 15, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 25, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 23, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | June 3, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 31, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | August 1, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | August 3, 2016 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Standard Biotools disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Standard Biotools sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
151 figures on this page: 140 cited to the filing that reported them, 11 calculated from figures it prints.
140 cited to the filing
11 calculated from the filing
Documents cited
- 0001193125-26-275946Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-26-0171002025 Director Compensation · Executive Officer and Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End for 2025 · and 1 more section
- 0000950170-25-088519Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-24-076823
- 0001162194-23-000033
- 0001162194-22-000067
- 0001162194-21-000048
- 0001162194-20-000076
- 0001171843-19-003846
- 0001171843-18-004371
- 0001144204-17-039703
- 0001193125-16-671853
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Standard Biotools executive compensation, FY2025.” https://intel.velarion.ai/comp/LAB (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Standard Biotools and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Standard Biotools discloses
The companies named in LAB's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}